News

ANI Pharmaceuticals price target raised to $65 from $62 at Truist
Truist analyst Les Sulewski raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $65 from $62 and keeps a Hold rating on the shares ...
Business Insider1mon
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide ...
Yahoo Finance27d
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
The replay of the webcast will be accessible for 60 days. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its ...